Gsk (GSK) Cash from Operations (2009 - 2026)

Gsk (GSK) has 18 years of Cash from Operations data on file, last reported at $5.1 billion in Q3 2026.

• For the quarter ending Q3 2026, Cash from Operations changed N/A year-over-year to $5.1 billion; the trailing twelve-month figure through Sep 2026 stood at $14.6 billion (changed N/A YoY), and the FY2025 full-year result was $10.3 billion, up 22.91% from the prior year.
• Cash from Operations was $5.1 billion for Q3 2026 at Gsk, up from $3.6 billion in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of $5.1 billion in Q3 2026 to a low of $64.4 million in Q1 2023.
• A 5-year average of $2.4 billion and a median of $2.8 billion in 2025 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations slumped 97.82% in 2023 and soared 1786.37% in 2024, its largest moves.
• Gsk's Cash from Operations stood at $4.0 billion in 2022, then plunged by 57.7% to $1.7 billion in 2023, then surged by 77.09% to $3.0 billion in 2024, then soared by 44.22% to $4.3 billion in 2025, then grew by 19.31% to $5.1 billion in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were $5.1 billion in Q3 2026, $3.6 billion in Q2 2026, and $1.5 billion in Q1 2026.